Integra LifeSciences (NASDAQ:IART) Reaches New 1-Year Low at $31.53

Integra LifeSciences Holdings Co. (NASDAQ:IART) shares reached a new 52-week low during trading on Thursday . The stock traded as low as $31.53 and last traded at $31.57, with a volume of 232579 shares. The stock had previously closed at $31.94.

Analyst Ratings Changes

IART has been the subject of several analyst reports. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Friday, April 5th. Truist Financial cut their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a report on Friday, March 1st. Citigroup raised shares of Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. Finally, JMP Securities cut their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $44.89.

Integra LifeSciences Stock Performance

The company’s 50-day moving average price is $37.32 and its two-hundred day moving average price is $39.19. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. The stock has a market cap of $2.49 billion, a PE ratio of 38.48, a PEG ratio of 0.96 and a beta of 1.12.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.01). The company had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a net margin of 4.39% and a return on equity of 15.19%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 EPS. On average, equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

Large investors have recently added to or reduced their stakes in the business. Swiss National Bank raised its position in Integra LifeSciences by 0.9% in the 3rd quarter. Swiss National Bank now owns 161,994 shares of the life sciences company’s stock worth $6,187,000 after purchasing an additional 1,500 shares during the period. Deerfield Management Company L.P. Series C purchased a new position in Integra LifeSciences in the 3rd quarter worth $43,034,000. Cardinal Capital Management increased its position in shares of Integra LifeSciences by 1.6% in the fourth quarter. Cardinal Capital Management now owns 22,101 shares of the life sciences company’s stock valued at $962,000 after acquiring an additional 347 shares during the period. Assenagon Asset Management S.A. purchased a new position in shares of Integra LifeSciences in the third quarter valued at about $25,443,000. Finally, Vanguard Group Inc. increased its position in shares of Integra LifeSciences by 1.0% in the third quarter. Vanguard Group Inc. now owns 7,159,854 shares of the life sciences company’s stock valued at $273,435,000 after acquiring an additional 72,294 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.